Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Pseudomonas Infections 1Pneumonia 1Hematologic Neoplasms 1Gram-Negative Bacterial Infections 1Bacteremia 1

Interventions

Cyclophosphamide 222pembrolizumab 201Carboplatin 173Cisplatin 168Gemcitabine 167Paclitaxel 155Docetaxel 140Bevacizumab 138Rituximab 137Radiotherapy 137Nivolumab 126Dexamethasone 126Capecitabine 103fludarabine 102Pemetrexed 92fludarabine phosphate 91Fluorouracil 91Doxorubicin 85Oxaliplatin 79Etoposide 77Cytarabine 77Bortezomib 76Erlotinib Hydrochloride 74Leucovorin 72Filgrastim 68Lenalidomide 67Calcium Dobesilate 66Irinotecan 65atezolizumab 63Radiation 61

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Has results × ceftolozane, tazobactam drug combination × Clear all
NCT04673175 2026-01-21

Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

Weill Medical College of Cornell University

Phase 4 Terminated
17 enrolled 20 charts
Other hematologic neoplasm

Pneumonia, Pseudomonas Infections, Bacteremia, Gram-Negative Bacterial Infections, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡